Core Viewpoint - China Medical (600056) announced that its wholly-owned subsidiary Tianfang Pharmaceutical (600253) received two drug registration certificates for hydrochloride urapidil injection from the National Medical Products Administration, which is primarily used for treating hypertensive crises and severe hypertension [1] Company Summary - The drug is intended for the treatment of hypertensive crises, severe and extremely severe hypertension, as well as refractory hypertension, and for controlling perioperative hypertension [1] - The registration application was accepted by the National Medical Products Administration in February 2024, with research and development investments amounting to approximately 7.31 million yuan [1] - The company aims to enrich its cardiovascular medication product line with this new registration [1] Industry Summary - A total of 28 domestic production enterprises have obtained approval for this drug, with the total domestic sales in 2023 estimated at approximately 1.072 billion yuan and projected to be around 801 million yuan in 2024 [1] - Future sales may face risks of not meeting expectations due to policy and market environment influences [1]